Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial
By M. Simons, B. Annex, R. Laham, N. Kleiman, T. Henry, H. Dauerman, J. Udelson, E. Gervino, M. Pike, M. J. Whitehouse and 2 more. Circulation, 2002
697 citations recorded by the source corpus.
Subfields: Anesthesiology and Pain Medicine, Molecular Biology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/4d991f600b58cfaf28053c04aeddf39b7dcdd2b5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- A review on coronary artery disease, its risk factors, and therapeutics (2019, background): “Through tyrosine kinase receptors (Klint & Claesson‐Welsh, 1999) and syndecan 4 heparin sulfate core protein (Simons et al., 2002), the fibroblast growth factor triggers signals and increases the expression of such receptors in the ischemic myocardium, thereby promoting responsiveness to FGF2…”
- The FGF family: biology, pathophysiology and therapy (2009, neutral): “However, in the FGF Initiating RevaScularization Trial (FIRST), FGF2 treatment conferred some benefit in the first few months, but these improvements were not sustained, whereas continued improvement was seen in the placebo grou”
- Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 (2003, background): “A recent FGF-2–based random, double-blind, controlled trial of FGF-2 in the treatment of coronary artery disease showed trends toward short-term, but not long-term, symptomatic improvemen”
- FGF/FGFR signaling in health and disease (2020, background): “Some clinical trials demonstrated that FGF2 administration can improve the symptoms of patients with coronary artery disease or peripheral artery disease.(448,479) In addition, inhibition of FGF2/FGFR1 by antisense cDNAs blocked intratumoral angiogenesis and arrested the growth of human melanomas gr”
- Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. (2005, background): “Transient beneficial effects were observed also in the phase II trial FIRST in which FGF2 was administered via intracoronary infusion [238].”